TSXV:BGA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioNeutra Global Corporation, together with its subsidiaries, engages in the research and development, production, and commercialization of food ingredients for nutraceutical, functional, and mainstream foods and beverages with a focus on oligosaccharides.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has BioNeutra Global's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BGA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

BGA

3.1%

CA Personal Products

-0.5%

CA Market


1 Year Return

-66.3%

BGA

-1.8%

CA Personal Products

-12.7%

CA Market

Return vs Industry: BGA underperformed the Canadian Personal Products industry which returned -3.4% over the past year.

Return vs Market: BGA underperformed the Canadian Market which returned -12.4% over the past year.


Shareholder returns

BGAIndustryMarket
7 Day0%3.1%-0.5%
30 Day-28.6%4.4%-3.2%
90 Dayn/a34.1%7.8%
1 Year-66.3%-66.3%-1.2%-1.8%-9.6%-12.7%
3 Year-66.7%-66.7%105.2%98.6%3.0%-6.9%
5 Yearn/a72.6%72.6%19.1%1.1%

Price Volatility Vs. Market

How volatile is BioNeutra Global's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioNeutra Global undervalued compared to its fair value and its price relative to the market?

1.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BGA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BGA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BGA is unprofitable, so we can't compare its PE Ratio to the Personal Products industry average.

PE vs Market: BGA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BGA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BGA is overvalued based on its PB Ratio (1.5x) compared to the CA Personal Products industry average (1.3x).


Next Steps

Future Growth

How is BioNeutra Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

33.5%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioNeutra Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BioNeutra Global performed over the past 5 years?

-59.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BGA is currently unprofitable.

Growing Profit Margin: BGA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BGA is unprofitable, and losses have increased over the past 5 years at a rate of -59.7% per year.

Accelerating Growth: Unable to compare BGA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BGA is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (18.7%).


Return on Equity

High ROE: BGA has a negative Return on Equity (-261.83%), as it is currently unprofitable.


Next Steps

Financial Health

How is BioNeutra Global's financial position?


Financial Position Analysis

Short Term Liabilities: BGA's short term assets (CA$20.6M) do not cover its short term liabilities (CA$22.5M).

Long Term Liabilities: BGA's short term assets (CA$20.6M) exceed its long term liabilities (CA$6.7M).


Debt to Equity History and Analysis

Debt Level: BGA's debt to equity ratio (159.5%) is considered high.

Reducing Debt: BGA's debt to equity ratio has increased from 2.8% to 159.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BGA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BGA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 26.4% per year.


Next Steps

Dividend

What is BioNeutra Global current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BGA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BGA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BGA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BGA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BGA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Jianhua Zhu

5.75yrs

Tenure

CA$187,952

Compensation

Dr. Jianhua Zhu, Ph.D., is Founder and has been Chief Executive Officer of BioNeutra Global Corporation since October 2014 and serves as its President. Dr. Zhu has been Chief Executive Officer and Director ...


CEO Compensation Analysis

Compensation vs Market: Jianhua's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD175.49K).

Compensation vs Earnings: Jianhua's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jianhua Zhu
Founder5.75yrsCA$187.95k0.35% CA$24.5k
Branko Jankovic
Chief Financial Officer0.17yrno datano data
Warren Michaels
Vice-President of Communications & HR2.17yrsno datano data
Sheri O'Brien
Vice President of Sales & Marketing1.5yrsno datano data
Monica Barclay
Corporate Secretaryno datano datano data

1.8yrs

Average Tenure

Experienced Management: BGA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jianhua Zhu
Founder5.75yrsCA$187.95k0.35% CA$24.5k
Curtis Sparrow
Chairman0.25yrno datano data
Chuen Hing Cheung
Independent Director0.92yrCA$66.02k0.79% CA$55.3k
Jason Theiss
Director0.92yrno datano data
William Wei
Director0.92yrno datano data

0.9yrs

Average Tenure

Experienced Board: BGA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioNeutra Global Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioNeutra Global Corporation
  • Ticker: BGA
  • Exchange: TSXV
  • Founded:
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: CA$6.967m
  • Shares outstanding: 46.45m
  • Website: https://www.bioneutra.ca

Number of Employees


Location

  • BioNeutra Global Corporation
  • 9608-25 Avenue NW
  • Edmonton
  • Alberta
  • T6N 1J4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BGATSXV (TSX Venture Exchange)YesCommon SharesCACADOct 2015

Biography

BioNeutra Global Corporation, together with its subsidiaries, engages in the research and development, production, and commercialization of food ingredients for nutraceutical, functional, and mainstream foods and beverages with a focus on oligosaccharides. Its lead product is VitaFiber, an isomalto-oligosaccharide functional and health food ingredient that offers low calorie and soluble prebiotic fiber for human digestive health. The company serves small and medium enterprises, and various food and beverage manufacturers in Canada, the United States, Europe, Australia, New Zealand, and internationally. It also provides VitaFiber through Amazon.com and Shopify.com, as well as other direct-to-consumer retailers. BioNeutra Global Corporation is based in Edmonton, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/10 00:13
End of Day Share Price2020/06/23 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.